The IFN-high phenotype: A biomarker-driven breakthrough in colorectal cancer treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40107241.
- Also identified by DOI 10.1016/j.xcrm.2025.102025 and PMC identifier 11970388.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patient stratification is crucial for improving immunotherapy effectiveness. Acha-Sagredo et al. identified an interferon (IFN)-high immunophenotype and CD74 overexpression as predictors for immunotherapy response in colorectal cancer (CRC). This signature, involving cytotoxic T cells and antigen-presenting macrophages, was found in both mismatch repair-deficient and -proficient CRCs. CD74 overexpression could serve as a biomarker, enabling personalized CRC treatment.
Medical subject headings
- Colorectal Neoplasms
- Biomarkers, Tumor
- Interferons